首页> 美国卫生研究院文献>Cardiovascular Diabetology >Treatment with pioglitazone induced significant reversible mitral regurgitation
【2h】

Treatment with pioglitazone induced significant reversible mitral regurgitation

机译:吡格列酮治疗可引起明显的可逆性二尖瓣关闭不全

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

There has in recent years been great concern about possible cardiac side effects of thiazolidinediones (TZDs). We present a case-report of a 60 year-old male who developed significant mitral regurgitation during six months treatment with pioglitazone in parallel with laboratory indications of fluid retention. Echocardiography six months after discontinuation of medication showed regression of mitral regurgitation and the laboratory parameters were also normalized. It is noteworthy that six months treatment with pioglitazone could induce significant valve dysfunction, which was reversible, and this underlines the importance of carefully monitoring patients when placing them on treatment with TZDs.
机译:近年来,人们对噻唑烷二酮类药物(TZDs)可能产生的心脏副作用产生了极大的关注。我们提供了一个60岁男性的病例报告,该男性在使用吡格列酮治疗六个月期间出现明显的二尖瓣关闭不全,同时伴有体液retention留的实验室指征。停药六个月后的超声心动图显示二尖瓣反流消退,实验室参数也正常化。值得注意的是,吡格列酮治疗六个月可能会引起明显的瓣膜功能障碍,这是可逆的,这突出了在对患者进行TZD治疗时仔细监控患者的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号